Skip to content
Company Analysis

Harvard Bioscience, Inc. HBIO

A comprehensive view of key metrics, scores, and financial health for Harvard Bioscience, Inc.

Overview of Harvard Bioscience, Inc.

HBIO NCM
Healthcare Medical Instruments & Supplies Micro Cap
Harvard Bioscience, Inc. (HBIO), is a Micro Cap company, in the Medical Instruments & Supplies industry, last closed at $0.47, about 678.7% undervalued vs fair value, -32.9% 1Y return, ranked 763/1110 in sector.
$0.47
-4.08%
As of March 13, 2026
Previous close • Vol 90d: 90.4%
52-Week Range
Market Cap
$20.92M
Enterprise Value
$56.89M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Harvard Bioscience, Inc..

Top Beats
No strong beats yet

Quick Facts

Website https://www.harvardbioscience....
HQ Holliston, MA
Employees 330
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$3
$4
$4
Current: $0.47 +679% vs base

Engine Room Money Flow™

Micro Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$94.1M
-16.1%%
Gross Profit
$54.8M
-17.1%%
Operating Income
$-6.2M
-427.9%%
Net Income
$-12.4M
-263.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
14.7%
Poor

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
6
Active Leaks
1/6
Improving
0
High Impact
6
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Harvard Bioscience, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
46
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
55
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 92% Coverage
Trade-Off Triangle Visualization A ternary plot showing HBIO's balance between Growth (13.6%), Profitability (46.4%), and Safety (39.9%). Growth 14% Safety 40% Profitability 46%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

12th percentile vs peers
13
Key Signals
Revenue CAGR 3Y -7.5% 16p Rev Growth YoY -16.1% 12p EPS Growth YoY -2.54 7p
Strengths
  • D/E Ratio in top 20% of peers (70.2%, 81th percentile)
  • Net Debt/Ebitda in top 20% of peers (4.79, 80th percentile)
  • Conservative leverage compared to industry peers
Risks
  • Growth in bottom 20% of peers (percentile: 12)
  • Rev Growth Yoy in bottom 20% of peers (-16.1%)
  • Eps Growth Yoy in bottom 20% of peers (-2.54)

Profitability

42th percentile vs peers
43
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

36th percentile vs peers
37
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Harvard Bioscience, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$3.66
- - -
+678.7% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info